KPTI
NASDAQKaryopharm Therapeutics Inc.
Price$0.39+0.01 (+4.01%)
06:30 PM07:45 PM
News · 26 weeks56-57%
2026-04-262026-10-18
Mix2390d
- Other9(39%)
- SEC Filings7(30%)
- Insider3(13%)
- Analyst2(9%)
- Earnings2(9%)
Latest news
25 items- SECSEC Form 8-K filed by Karyopharm Therapeutics Inc.8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
- INSIDERChief Accounting Officer Abate Kristin sold $450 worth of shares (378 units at $1.19), decreasing direct ownership by 2% to 23,404 units (SEC Form 4) to satisfy withholding obligation4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- PRKaryopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of September 30, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversarie
- SECKaryopharm Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
- SECKaryopharm Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
- SECSEC Form SCHEDULE 13G filed by Karyopharm Therapeutics Inc.SCHEDULE 13G - Karyopharm Therapeutics Inc. (0001503802) (Subject)
- INSIDERChief Accounting Officer Abate Kristin sold $38 worth of shares (19 units at $2.02), decreasing direct ownership by 0.08% to 23,782 units (SEC Form 4) to satisfy tax liability4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- PRKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEWTON, Mass., Sept. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,850 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of August 31, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three cons
- SECSEC Form 8-K filed by Karyopharm Therapeutics Inc.8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
- PRKaryopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis– sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested – NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking Accelerated Approval for XPOVIO® (selinexor) in combination with ruxolitinib for patients with myelofibrosis. Karyopharm requested Priority Review of the application, which, if granted, could result in a six-month review process."Today's submission is an important step toward our goal of bringing the combination
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Karyopharm Therapeutics Inc.SCHEDULE 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)
- SECSEC Form 10-Q filed by Karyopharm Therapeutics Inc.10-Q - Karyopharm Therapeutics Inc. (0001503802) (Filer)
- SECKaryopharm Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
- PRKaryopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission– Planned August sNDA Submission for Selinexor in Combination with Ruxolitinib in Myelofibrosis under the Accelerated Approval Pathway Remains on Track – – Planned sNDA for Selinexor plus Ruxolitinib Supported by Phase 3 SENTRY Results Presented at ASCO and EHA and Published in the Journal of Clinical Oncology; Potential to Become the First Approved Combination Therapy for Patients with Myelofibrosis –– Total Revenue was $33.4 Million, and U.S. XPOVIO® (selinexor) Net Product Revenue was $30.8 Million for the Second Quarter of 2026 –– Company Reaffirms Full-Year 2026 Total Revenue Guidance of $130 Million to $150 Million Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Karyopharm Therapeutics Inc.SCHEDULE 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)
- PRKaryopharm to Report Second Quarter 2026 Financial Results on August 13, 2026-- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET --NEWTON, Mass., Aug. 10, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2026 financial results on Thursday, August 13, 2026. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, August 13, 2026, to discuss the financial results and other company updates.To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Kar
- PRKaryopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NEWTON, Mass., Aug. 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of July 31, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of
- ANALYSTKaryopharm Therapeutics downgraded by Robert W. Baird with a new price targetRobert W. Baird downgraded Karyopharm Therapeutics from Outperform to Neutral and set a new price target of $3.00
- ANALYSTKaryopharm Therapeutics downgraded by H.C. Wainwright with a new price targetH.C. Wainwright downgraded Karyopharm Therapeutics from Buy to Neutral and set a new price target of $3.00
- SECSEC Form 8-K filed by Karyopharm Therapeutics Inc.8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
- INSIDEREVP, Chief Development Officer Poulton Stuart sold $1,342 worth of shares (189 units at $7.10), decreasing direct ownership by 0.20% to 94,632 units (SEC Form 4) (withholding tax)4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
- PRKaryopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review –– Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data and Preliminary Overall Survival Data Observed at the Time of the Topline Results – – Company Plans to Use Long-Term Overall Survival Data from the Ongoing Phase 3 SENTRY Trial to Verify Clinical Benefit –– If Approved, Selinexor in Combination with Ruxolitinib has the Potential to Become the First Approved Combination Therapy for Patients with Myelofibrosis, Adding a Novel Class of Therapy –NEWTON, Mass., July 30, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage
- PRKaryopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer– The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival (PFS) –– A Trend Favoring the Selinexor Arm was Observed with a 5.3 Month Improvement in Median PFS Relative to the Placebo Arm in the mITT Population; Company Plans to Continue to Follow Patients for Longer-Term Outcomes –– The Safety and Tolerability Profile was Consistent with the Known Profile of Selinexor; No New Safety Signals Were Observed –– Company Prioritizing its Resources on its Myelofibrosis and Multiple Myeloma Programs; Company to Reduce Planned Investment in Endometrial Cancer –NEWTON, Mass., July 30, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical com
- SECSEC Form 8-K filed by Karyopharm Therapeutics Inc.8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
- PRKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEWTON, Mass., July 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,649 restricted stock units (RSUs) to four newly-hired employees. These RSU awards were granted as of June 30, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consec
KPTI FAQ
7 questionsWhat does Karyopharm Therapeutics Inc. do?
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company's lead compound, XPOVIO (selinexor), is approved in the U.S. in various hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with...Where does KPTI stock trade?
Karyopharm Therapeutics Inc. (KPTI) is listed on NASDAQ.What sector and industry is KPTI in?
Karyopharm Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Karyopharm Therapeutics Inc. go public?
Karyopharm Therapeutics Inc. (KPTI) completed its IPO in 2013.What are analysts saying about KPTI?
Karyopharm Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral with a $300.00 price target on 2026-07-31.What companies are similar to KPTI?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare KPTI side-by-side with any of them on Quantisnow.How can I track KPTI on Quantisnow?
Quantisnow aggregates Karyopharm Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KPTI to receive live email and push alerts on every new disclosure.